Corporate
BioNK-c is a pioneering biotechnology company focused on the development, manufacturing, distribution, and marketing of advanced NK immune cellular therapy products. Based in the USA, with a strong emphasis on Brazil, we operate within a growing market driven by a robust universal healthcare system, ensuring widespread access to life-saving medicinal products for all citizens.
Learn moreProduct Information
Overall, BioNK is a promising avenue for cancer immunotherapy, offering the potential for targeted, off-the-shelf treatments with broad applicability across different cancer types. Ongoing research and clinical development efforts aim to further optimize BioNK cell-based therapies and expand their utility in the treatment of cancer.
Learn moreMarket and Target Audience
BioNK-c will primarily develop and market its immune cellular therapy products to Brazil.
Brazil’s universal healthcare system presents an exceptional challenge for biologic and cell therapy products.
With a vast population and a commitment to accessible healthcare, the Brazilian market is ground for BioNK-c’s innovative therapies to make a meaningful impact.
Brazil’s health expenditure was over U$ 180 billion in 2021 for its 215 million inhabitant less than U$ 1,124 per capita, against U$ 13,000 in the USA.
Brazil’s Universal Health System is responsible for ½ of the population with a budget of only U$ 32 billion.